Scholtz & Company’s Acutus Medical Inc AFIB Stock Holding History

Scholtz & Company’s Portfolio AFIB Stock Details AFIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-128,140	Closed	-$3.69M	–	85
2020 Q4	$3.69M	Buy	+128,140	New	+$3.47M	1.44%	30

Other funds holding AFIB

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return

Scholtz & Company's AFIB Position: Q1 2021 in Review

Scholtz & Company sold out of Acutus Medical Inc (AFIB) in Q1 2021, closing a stake of 128,140 shares — an estimated $3.69M sold.

Scholtz & Company first reported a position in AFIB in Q4 2020 and held it in 1 quarter. The position peaked at $3.69M in Q4 2020. 67 funds tracked by Wall St. Rank hold AFIB as of Q1 2021.

Scholtz & Company reported no remaining Acutus Medical Inc position as of Q1 2021 after selling out during the quarter.
Scholtz & Company sold 128,140 Acutus Medical Inc shares in Q1 2021, an estimated $3.69M.
Scholtz & Company first reported a position in Acutus Medical Inc in Q4 2020 and held it in 1 quarter.
Scholtz & Company's Acutus Medical Inc position peaked at $3.69M in Q4 2020.
67 funds tracked by Wall St. Rank held Acutus Medical Inc as of Q1 2021.

Based on Scholtz & Company's 13F filing for Q1 2021, filed 17 May 2021.